Follow The Filings

BBIO Bridgebio Pharma Inc.

Health Care, filed as BRIDGEBIO PHARMA INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 2

  • 4 Owners
  • Max 3.7%
  • $1.5B
  • 1 add 2 reduce

In 2026 Q2 Farallon Capital Management added to Bridgebio Pharma, while Andreas Halvorsen and Polen Capital Management trimmed.

Who owns this now

Largest portfolio weights among holders, up to 3.7% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Add 3.7%
  2. Andreas Halvorsen Reduce 2.1%
  3. David Witzke 0.12%

Who owns BBIO

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management 3.7% Add +14.7% 10,743,063 $800M History
Andreas Halvorsen, Viking Global Investors 2.1%, was 2.5% Reduce −16.0% 9,949,219 $741M History
David Witzke, Avidity Partners Management 0.12% Hold 10,000 $745K History
Polen Capital Management <0.01%, was 0.02% Reduce −91.3% 4,002 $298K History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BBIO insider trades
  • None no insider bought on the open market
  • $11.9M sold by 3 insiders outside a trading plan
  • $93.2M sold by 7 insiders under 10b5-1 plans
  1. Neil Kumar CEO
    Planned sale
    $691K 10,000 shares at $69.08 2% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  2. Neil Kumar CEO
    Planned sale
    $3.7M 44,980 shares at $82.86
    Traded Aug 18–19 Filed Aug 20
    ↗
  3. Maricel Apuli Chief Accounting Officer
    Planned sale
    $160K 2,000 shares at $80.06 1.5% of stake
    Traded Jul 30 Filed Aug 3
    ↗
  4. Andrea Ellis Director
    Planned sale
    $1.4M 17,167 shares at $84.00 43% of stake
    Traded Jul 9 Filed Jul 13
    ↗
  5. Jennifer E. Cook Director
    Planned sale
    $13.2M 148,589 shares at $88.54 95% of stake
    Traded Jul 9 Filed Jul 13
    ↗
  6. Jennifer E. Cook Director
    Planned sale
    $2.8M 39,363 shares at $69.92 82% of stake
    Traded Jun 23–24 Filed Jun 24
    ↗
  7. Hannah Valantine Director
    Planned sale
    $342K 5,004 shares at $68.25 35% of stake
    Traded Jun 22–23 Filed Jun 24
    ↗
  8. Jennifer E. Cook Director
    Planned sale
    $6M 90,240 shares at $66.62 93% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  9. Neil Kumar CEO
    Planned sale
    $5.4M 80,000 shares at $67.67 1.8% of stake
    Traded Jun 4–5 Filed Jun 8
    ↗
  10. Neil Kumar CEO
    Planned sale
    $1.8M 26,103 shares at $69.44 9.7% of stake
    Traded May 21 Filed May 26
    ↗
  11. Thomas Trimarchi CFO
    Planned sale
    $888K 13,651 shares at $65.08 3.7% of stake
    Traded May 18 Filed May 19
    ↗
  12. Randal W. Scott Director
    Planned sale
    $671K 10,000 shares at $67.15 46% of stake
    Traded May 15 Filed May 19
    ↗
  13. Neil Kumar CEO
    Planned sale
    $5.4M 80,000 shares at $67.40 1.8% of stake
    Traded May 7–8 Filed May 11
    ↗
  14. Maricel Apuli Chief Accounting Officer
    Planned sale
    $143K 2,000 shares at $71.58 1.5% of stake
    Traded Apr 30 Filed May 4
    ↗
  15. Neil Kumar CEO
    Planned sale
    $6M 80,000 shares at $74.61 1.8% of stake
    Traded Apr 9–10 Filed Apr 13
    ↗

Also filed in the last 12 months, not counted as buying or selling: 32 option exercises, 16 share withholdings for taxes, and 14 stock grants.

Congress

1 member of Congress traded BBIO in the last three years: 7 buys and 1 sale. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Sep 29 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K May 11 filed Jun 8
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Apr 29 filed May 8
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 19 filed Apr 7
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 18 filed Apr 7
  6. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B7 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,3.02,3.03,5.03,7.01,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $9.3M $221.9M $502.08M
Gross profit * $6.86M $218.02M $481.11M
Gross margin * 73.7% 98.3% 95.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $477.59M $720.69M $797.75M
Total non-current assets * $68.79M $198.65M $138.28M
Total assets $546.38M $919.34M $936.02M
Total current liabilities $143.84M $154.4M $287.97M
Total non-current liabilities * $1.75B $2.22B $2.72B
Total equity -$1.35B -$1.47B -$2.09B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$527.72M -$520.73M -$445.91M
Cash from investing $54.03M $60.78M -$24.49M
Cash from financing $451.54M $748.46M $359.29M
Net change in cash -$22.15M $288.51M -$111.1M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.